Navigation Links
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Date:12/8/2008

lations with biologics directed against Roche targets covered under the licensing and collaboration agreement. Halozyme continues to scale up its manufacturing processes to enhance yields and efficiencies in order to produce multi-kilogram quantities of enzyme. As specified in the agreement, Halozyme will supply rHuPH20 to Roche to fulfill all of its clinical development and commercialization requirements.

Halozyme Roche Collaboration

In December 2006, Halozyme entered into an agreement with Roche to apply Halozyme's proprietary Enhanze(TM) Technology to Roche's biological therapeutic compounds. Under the terms of the agreement, Roche paid Halozyme an initial payment for the application of its recombinant human enzyme, rHuPH20, to three pre-defined Roche biologic targets. Roche has now selected a fourth biologic target and has the option to exclusively develop and commercialize rHuPH20 with an additional nine targets. Pending the successful achievement of a series of clinical, regulatory, and sales events, Roche may pay Halozyme additional milestones as well as royalties on potential future product sales. Under the collaboration, Roche has access to Halozyme's expertise in developing and applying rHuPH20 to Roche targets. Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and Roche target compounds resulting from the collaboration.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
2. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
3. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
7. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
8. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
9. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
10. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
11. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma ... it will report its second quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems Market Outlook ... Capsule Endoscopy Systems market. The report provides value, in ... prices (in US dollars) within market segments: ... Capsule Endoscopes , Capsule Endoscopy Data Recorders ... also provides company shares and distribution shares data for ...
(Date:7/25/2014)... 25, 2014  CVS Caremark Corporation (NYSE: ... Tuesday, August 5, 2014, at 8:30 a.m. (EDT) with ... financial results. An audio webcast of the ... Relations portion of the CVS Caremark website for all ... . This webcast will be archived and available on ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5
... 07, 2007 /PRNewswire-FirstCall/ --,Mymetics Corporation announced today ... vaccine elicited neutralizing,IgA mucosal antibodies in a ... as a possible first line of defense,against ... by Sylvain,Fleury, Ph.D., Mymetics' Chief Scientific Officer, ...
... 7, 2007 - Dynogen,Pharmaceuticals, Inc. reported positive ... trial of DDP733 for,gastroesophageal reflux disease (GERD). ... DDP733 as a treatment for,nocturnal GERD (NGERD). ... significance over placebo on the primary endpoint ...
Cached Medicine Technology:Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 2Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 3Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 4Dynogen Reports Positive Results in Phase 1B GERD Study 2Dynogen Reports Positive Results in Phase 1B GERD Study 3Dynogen Reports Positive Results in Phase 1B GERD Study 4
(Date:7/28/2014)... July 28, 2014 A St. Jude ... adult survivors of childhood cancer more than doubled their ... by failing to follow a heart-healthy lifestyle. The results ... , Almost 32 percent of the 1,598 adult survivors ... an umbrella term for health risk factors like high ...
(Date:7/28/2014)... July 2014: ESC Congress 2014 promises to be bigger, ... Keith Fox, Chair of the Congress Programme Committee. The ... most influential cardiovascular event every year in August. Record ... this year and the congress is on track to ... , Asked why an extra hot line session ...
(Date:7/28/2014)... group of researchers in Taiwan has developed a new ... early complication of diabetes sooner, when it is more ... in clinical trials, it may pave the way for ... complication, called diabetic autonomic neuropathy, which is common among ... The condition progressively affects the autonomic nerves controlling vital ...
(Date:7/28/2014)... Brea, CA (PRWEB) July 28, 2014 ... management business process outsourcing (BPO) for Fortune 500 brands, ... 2,500 jobs across its locations in Wisconsin, California, Florida ... will be based at its Brea campus. , A ... clients, which have seasonal ramp-ups that require additional staffing ...
(Date:7/28/2014)... Brisbane, Australia (PRWEB) July 28, 2014 ... achieve a happier lifestyle can often be a struggle ... international channel, psychic and medium, Lynette Leckie-Clark provides simple ... new book “The Magic of You.” With inspiring spiritual ... thinking, you can find empowerment, confidence and motivation for ...
Breaking Medicine News(10 mins):Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 2Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 3Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 4Health News:ESC Congress 2014 focuses on innovations in cardiology 2Health News:ESC Congress 2014 focuses on innovations in cardiology 3Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 3Health News:Be Empowered to Achieve Happiness from New Book "The Magic of You" 2
... being fed contaminated feed is causing concern among the people. The ... years . The FDA is quick to play down the fear ... ,This concern came to light after some 38 chicken farms in ... farms fed the chicken for human consumption with the contaminated feed. ...
... C (HCV), survival has improved over time. However, for ... to a study in the issue of Liver Transplantation. ... reason for liver transplantation in the U.S., however, previous ... as well to liver transplantation. The difference has become ...
... governor, James E. McGreevy appears to be knocking on a ... the news for the right reasons. He has been ... ,Former Gov. James E. McGreevy, who was brought up as ... on Sunday at St. Bartholomew's Church in New York. He ...
... said the government is working to draft a law allowing ... of genetic disorders. ,"We are studying it from ... choice to have the abortion will be under the umbrella ... religious and social environment," Ali Shakar of the ministry of ...
... more than twice as likely to also have symptoms of ... not have migraines, according to research. ,The study involved ... screening questionnaire within 90 days after returning from one year ... the soldiers, or 60 percent, completed the questionnaire. Of those, ...
... warming, but only few act. ,The ... has two parts. One, human beings get stubbornly comfortable in ... programmed to act in its own best interests - and ... point. ,In addition, the overwhelming size and abstract ...
Cached Medicine News:Health News:Tainted Pet Food a Health Risk for Human? 2Health News:HCV Patients Survival After Liver Transplantation is Not Improving 2Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2Health News:Why Humans Fail to Act on Climate Change 2Health News:Why Humans Fail to Act on Climate Change 3
... operating and recovery room, ,The Cardiocap ... haemodynamic and airway gas monitoring for induction ... units. The Cardiocap II is available in ... haemodynamic measurements. Two of the models include ...
Precordial Chestpieces are manufactured from chrome plated brass. Provides a hollow design with deep sound chambers for optimum acoustics....
For accurately monitoring heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: